Articles tagged with Drug Studies
A new genetic test has identified patients with triple negative early-stage breast cancer who are unlikely to respond to immunotherapy drugs. The test, called ImPrintTN, can predict a patient's likelihood of responding to these treatments and help avoid severe side effects.
Recent medications for Type 2 diabetes and weight loss have positive effects on cardiovascular and kidney health but are not always prescribed or accessible to those who need them. The studies highlight the need to address barriers to access and equity, particularly among Black adults with severe obesity.
The ALEXANDRA/IMpassion030 phase 3 trial found that adding atezolizumab to chemotherapy after surgery did not improve survival for early-stage triple-negative breast cancer patients. Researchers also found no benefit in different sub-groups, such as those with lymph node spread and PD-L1 positive cancer.
A new international study led by UNSW Sydney found no increased risk of neurodevelopmental disorders and learning difficulties after exposure to antipsychotics during pregnancy. The study tracked the long-term risk of intellectual disability, poor academic performance in maths and language, or learning, speech and language disorders.
Researchers at Flinders University have discovered a bedtime nasal spray that can reduce the severity of sleep apnea in people and lower their blood pressure. The study found that the spray, which blocks potassium channels, improved oxygen levels and reduced markers of OSA severity in 7 out of 10 participants.
A phase 3 trial co-led by a University of Cincinnati researcher found that subcutaneous levodopa delivery through an infusion pump is safe and effective in reducing symptoms for longer periods. The study resulted in almost two hours of additional 'on time' compared to traditional oral medication, paving the way for potential FDA approval.
Rutgers Health researcher found that lesbian/gay and bisexual women are more receptive to tobacco marketing and have a harder time quitting. The study also discovered that bisexual women smoke at higher rates and struggle with nicotine addiction.
New research shows tirzepatide consistently reduces bodyweight and waist circumference, with greater reductions in participants with longer disease durations. Tirzepatide also achieves higher weight loss targets and reduces waist circumference more significantly than placebo across all disease duration categories.
A new analysis shows that tirzepatide effectively reduces body weight across different BMI subgroups, achieving significant weight loss of 5% or more in up to 100% of participants. The treatment also demonstrated superior weight reduction compared to placebo in patients with type 2 diabetes.
Research reveals oestrogen's protective role in preventing fatty liver disease by targeting the TEAD1 protein. The discovery could lead to a new treatment for fatty liver and liver cancer, as well as earlier detection methods.
Research from UCSF found COVID antigens lingering in blood up to 14 months and tissue samples for over two years after infection. The persistence of these fragments may drive long COVID symptoms and associated risks.
A recent study at Salk Institute evaluates the reliability of patient-derived organoids as a clinical model for pancreatic cancer. The findings reveal that organoids' gene expression and drug responses are not affected by commercial extracellular matrix brands, but one product increases growth rate.
A study published in JAMA Surgery found that 56% of patients using GLP-1 RAs had significant gastric contents on ultrasound before elective procedures, despite adequate fasting. The study suggests that conventional fasting times may need to be reexamined for this patient subset.
A University of Cincinnati study found liraglutide to be efficacious and safe for weight loss in individuals with stable bipolar disorder, without destabilizing the illness. The drug reduced binge eating behavior and significantly lowered hemoglobin A1C levels.
The NCI-MATCH precision medicine trial discovered that trastuzumab-pertuzumab, approved for HER2-positive breast cancer, can shrink tumors in patients with other types of cancer and high levels of the HER2 gene. The study found a 12% confirmed overall response rate, with partial responses in various cancers.
A research team developed a model of the blood-brain barrier using modularized tissue derived from human cells. The 'Tissue-in-a-CUBE' system accurately mimics the real blood-brain barrier in terms of structure and function, allowing for the testing of drugs without animal testing.
Researchers at University at Buffalo propose a new approach to developing cancer drugs by determining the optimal placement of molecular linkers earlier in the process, reducing trial and error and increasing potency, according to a study published in Communications Chemistry.
Researchers at Johns Hopkins Medicine have reported promising results from a clinical trial testing a novel immunotherapy combination to target advanced, potentially lethal skin cancers in kidney transplant patients. Two out of six patients experienced complete tumor regression after adding a second checkpoint inhibitor to the regimen.
New research reveals women's cardiovascular disease risks differ by age, lifestyle factors, and mental health conditions. Studies show sedentary behavior increases risk of death from all causes, while preeclampsia is linked to diet, highlighting need for targeted prevention strategies.
A survey study reveals primary care pediatricians lack preparedness in managing adolescent OUD, with a notable gap compared to other substance use disorders. The results underscore the importance of workforce training programs to address this critical healthcare issue.
Researchers found GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells, activating key pathways including ATM, AMPK, NFκB, and macroautophagy. The compound's unique multi-factorial mechanism suggests potential for treating mycosis fungoides.
A combination of CS1002 and CS1003 showed promising anti-tumor activity and a manageable safety profile across various dosing ranges in patients with advanced solid tumors. The treatment was found to be effective in certain types of cancers, including melanoma and skin cancer.
A new study suggests that Mark Cuban Cost Plus Drug Company (MCCPDC) may offer significant savings for patients taking common urology medications, with the greatest potential to reduce costs being for solifenacin and oxybutynin. The online pharmacy's standardized pricing can reduce out-of-pocket costs by up to $20 per prescription.
A phase 2 study by Mount Sinai-led researchers demonstrates rusfertide's ability to limit excess red blood cell production in patients with polycythemia vera, a rare and chronic blood cancer. The results suggest it could replace therapeutic phlebotomy, providing improved treatment options for patients.
A new study suggests that finasteride, a common hair loss and prostate drug, may also lower cholesterol levels and reduce cardiovascular disease risk in men. In mice, the researchers found significant correlations between finasteride use and lower cholesterol levels, as well as reduced inflammation and atherosclerosis progression.
The FDA has approved omalizumab for the reduction of allergic reactions, including anaphylaxis, in adults and children aged 1 year and older with food allergy. The approval is based on data from a Phase 3 clinical trial sponsored by NIAID.
Researchers developed a framework for standardizing biomarker development and validation to improve the prediction of age-related health outcomes. The study highlights the need for expanded focus on functional decline, frailty, chronic disease, and disability, and calls for harmonization of omic data to enhance reliability.
A four-drug chemotherapy regimen, NALIRIFOX, has been approved by the FDA for frontline treatment of metastatic pancreatic adenocarcinoma. The regimen, combining irinotecan liposome, oxaliplatin, leucovorin, and fluorouracil, resulted in longer overall survival compared to a two-drug protocol.
A new treatment combining a novel drug with traditional chemotherapy has been shown to increase the survival of patients with malignant mesothelioma, a rare and aggressive cancer. The ATOMIC-meso trial found that this treatment quadrupled the survival at 36 months compared to placebo-chemotherapy.
A new analysis reveals that approximately 30-90% of first-time mothers worldwide receive medical augmentation with oxytocin, despite only 10-15% experiencing prolonged labor. This excessive treatment increases the risk of stillbirths, brain damage, and complications for subsequent pregnancies.
Researchers use bacteriophages to target and kill drug-resistant bacteria, with a patient experiencing complete resolution of infection after combination therapy. However, immune response may lead to recurrence, highlighting need for further clinical trials.
Researchers developed an AI algorithm to analyze brain scans and clinical data, predicting treatment response with 8-week accuracy.
Researchers found that adding blood thinners to clot-busting medications for ischemic strokes did not improve physical function at 90 days post-stroke. The study, MOST, enrolled 514 patients and analyzed the effectiveness of two blood-thinning medications.
The study evaluated the effectiveness of ruxolitinib in treating relapsed/refractory multiple myeloma. Researchers found that ruxolitinib inhibited JAK signaling, leading to enhanced anti-tumor effects and improved patient outcomes.
A new type of cell therapy has shown promising results in improving survival rates and reducing pneumonia among critically ill ARDS patients recovering from severe Covid-19. The invariant natural killer T (iNKT) cell therapy, known as agenT-797, triggered an anti-inflammatory response and activated anti-viral immunity.
A new study published in the American Heart Association journal Hypertension found that tirzepatide significantly lowered systolic blood pressure levels in nearly 500 adults with obesity. The results suggest treating obesity with this weight loss medication may be an effective strategy for preventing or treating high blood pressure.
The lack of synergy between academia and industry in drug discovery hinders the development of effective treatments. Researchers discuss why many therapeutic molecules fail to reach clinical trials despite pre-clinical efficacy.
Researchers at Germans Trias i Pujol Research Institute have identified a combination of drugs that could change the treatment of patients with prostate cancer resistant to docetaxel. The study proposes a new treatment based on a combination of kinase inhibitors in patients who inevitably stop responding to docetaxel.
A study found that tenecteplase is safe and effective for treating ischemic stroke in mobile stroke units, offering a simpler alternative to alteplase. The new medication requires only a single injection, reducing administration time and complications.
A phase II clinical trial found Muse cell-based product CL2020 to be highly tolerated and improved ALS symptoms, but may not halt disease progression. The treatment's efficacy depends on combining it with other drugs for future treatments.
A study published at the American Stroke Association's International Stroke Conference 2024 found that treating people with ischemic stroke with intravenous injections of a combination of biologically active components of ginkgo biloba during the first two weeks after the stroke improved early cognitive recovery. The treatment, called ...
A combination of two cancer drugs has shown promise in treating malignant peripheral nerve sheath tumors (MPNSTs), a type of cancer that is notoriously hard to treat. The study found that the combination therapy of SHP2 inhibitors and CDK4/6 inhibitors suppressed tumor growth and triggered cell death in mouse models.
Researchers found that SGLT2 inhibitors reduced kidney stone rates by 30% compared to GLP1 agonists and 25% compared to DPP4 inhibitors. The study included data from 716,406 adults with type 2 diabetes who took these medications.
A study of 215 veterans found that nearly half experienced significant depression score drops, while about one quarter saw a halving of their scores. About 15% achieved full remission after six weeks of ketamine infusions, suggesting the treatment can provide substantial relief for those with complex mental health needs.
A recent study published in the journal Blood revealed that hydroxyurea treatment resulted in a 60% reduction in severe or invasive infections among Ugandan children with sickle cell anemia. The findings provide powerful justification for hydroxyurea's use as a standard of care in Africa, which could ultimately save countless lives.
A phase 3 trial shows that adjuvant pembrolizumab therapy significantly prolongs overall survival in patients with clear-cell renal-cell carcinoma (ccRCC) at high risk for recurrence. The treatment reduces the risk of death by 38% compared to placebo.
A international academic consortium has identified 13 biomarkers that significantly improve the ability to accurately predict cardiovascular disease risk in people with type 2 diabetes. The standout biomarker was N-terminal pro b-type natriuretic peptide (NT-proBNP), which is currently used to monitor heart failure status in patients.
Researchers explore the use of traditional Chinese medicine (TCM) compounds for treating non-alcoholic fatty liver disease (NAFLD) and improving sensitivity to radiation therapy for lung cancer. TCM compounds, such as oridonin and ginsenoside Rg5, have demonstrated anti-inflammatory effects and radiosensitizing properties.
Researchers develop technology that alleviates retinal pathologies by targeting mitochondrial chaperone TRAP1, which is implicated in the breakdown of blood-retinal barrier and pathological neovascularization. This treatment approach holds great promise for revolutionizing the treatment landscape for ischemic retinopathy.
A nationwide study from Karolinska Institutet found that GLP1 agonists like Ozempic reduce the risk of cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease. Those who continued taking the medication for ten years were half as likely to develop severe liver disease.
A new study found that propranolol, a medication for high blood pressure, can lower anxiety levels in individuals with autism spectrum disorder. The study involved 69 patients and showed significantly reduced anxiety levels compared to a placebo group.
A study found that primary care physicians spent nearly 30 minutes more on EHR tasks between pre-pandemic and final year, with time spent outside of scheduled hours increasing significantly. This growth in EHR workload may contribute to burnout and affect decisions to cut back on clinic time or leave the profession.
A new international trial investigated the safety and efficacy of sabatolimab combined with hypomethylating agents in patients with myelodysplastic neoplasms. The study found manageable side effects, but no significant improvement in response rates or progression-free survival.
Gabapentinoid usage has continued to rise in the US, increasing from 4.0% in 2015 to 4.7% in 2021, according to a recent report. The study found that users continue to take these medications despite FDA warnings against combining them with other sedating medications.
Researchers identified genetic variants that predict response to treatment for preterm birth, a condition affecting one in 10 infants. High levels of mutations in certain genes are associated with lower response rates, suggesting a precision framework for future drug development.
A recent meta-analysis of 20,000 patients with Alzheimer's disease found no clinically significant improvement in cognitive or functional abilities from monoclonal antibody treatment. The studies also revealed a high risk of serious harms, including cerebral edema and death, associated with the use of these expensive medications.
Researchers have effectively targeted three distinct groups of cholangiocarcinoma, a lethal disease caused by liver fluke parasite or herbal carcinogen exposure. Experimental models show that specific treatments targeting these pathways can slow cancer growth and improve prognosis for CCA patients
A new study published in Oncogene highlights the effectiveness of MDX-124, a therapeutic drug targeting annexin-A1, which promotes tumour progression. High annexin-A1 expression levels correlate with poorer overall survival in various cancers.
A new peer-reviewed study suggests that cannabis is having no significant effect on people's use of opioids, taken outside of medical guidance. The findings have substantial implications for U.S. treatment programs, which still require patients to abstain from cannabis before qualifying for potentially life-saving treatment.
A multisite clinical trial will evaluate repurposed FDA-approved drugs as treatment options for patients with Rett syndrome, a rare genetic neurodevelopmental disorder affecting brain development. The study aims to find new therapies to improve the lives of individuals with Rett syndrome, potentially providing multiple treatment options.